ESR2 and diffuse large B-cell lymphoma: Silibinin, a natural estrogen receptor beta agonist, induced cell death and autophagy (in vivo and in vitro) and reduced tumor volume in vivo in Diffuse Large B-cell Lymphoma (DLBCL); thus, silibinin has the potential to be a therapeutic agent for the treatment of DLBCL [110].